The Rh Blood Group System in Forensic Context

The Rh antigens are carried on two non-glycosylated transmembrane proteins: the RhD protein (encoded by RHD) and the RhCE protein (encoded by RHCE). Both genes sit in a head-to-tail arrangement on chromosome 1p36.11 and are about 97% homologous at the nucleotide level. RHD encodes the D antigen exclusively. RHCE encodes the C/c and E/e antigens, with different alleles producing Cc, cE, ce, and CE combinations. The proteins span the red cell membrane 12 times and are thought to function as ammonium transporters, though their exact physiological role remains under study.

Rh-negative individuals in most populations lack the RHD gene entirely; a deletion of the gene, not a non-functional allele, is the most common molecular basis of D-negativity in Europeans. In people of African descent, the RHD gene is more often present but silenced by a different mechanism, such as an altered promoter or an insertion element. This distinction matters for molecular typing: a PCR designed to amplify RHD exons may still yield a product in an African Rh-negative individual who has a non-functional RHD gene, leading to apparent discordance between genotype and phenotype.

Inheritance follows simple autosomal co-dominant genetics. Each parent contributes one Rh haplotype. Common haplotypes in European populations, in approximate frequency, are CDe (R1, ~42%), cde (r, ~37%), cDE (R2, ~14%), and CDE, Cde, and cdE at lower frequencies. The combined Rh phenotype of an individual is described by listing the antigens present: for example, a person who is D-positive, C-positive, c-positive, E-negative, and e-positive is written as DCcee, or as R1r in Wiener notation.

The D antigen is the primary target in both clinical and forensic Rh typing. The standard direct slide or tube agglutination test uses a commercial IgM anti-D reagent. IgM antibodies are large enough to bridge adjacent red cells in saline suspension and produce visible clumping within 30 to 60 seconds at room temperature. A 3% to 5% red cell suspension mixed with two drops of anti-D reagent on a tile, rocked gently, and examined over 60 seconds will show clear agglutination if D antigen is present. The test is rapid, inexpensive, and reliable for normal-expression D antigen.

Weak D variants express fewer D antigen sites per cell and cannot bridge IgM anti-D molecules at the spacing required for direct agglutination. Detection requires the indirect antiglobulin test (IAT). In the IAT, IgG anti-D is incubated with the red cells at 37 degrees Celsius for 30 to 60 minutes. This allows the smaller IgG antibody to coat the cells without bridging them. After incubation, unbound IgG is removed by multiple washes. Anti-human globulin (Coombs reagent) is then added; it binds to the Fc regions of the IgG molecules already attached to adjacent cells, cross-linking them into visible agglutination. A positive IAT but negative direct test indicates weak D.

The C, c, E, and e antigens are typed by the same direct agglutination principle, using IgM or IgG commercial reagents specific for each antigen. Full Rh phenotyping of a blood sample requires testing with anti-D, anti-C, anti-c, anti-E, and anti-e, producing a five-antigen phenotype. The phenotype is then compared against population frequency tables to calculate the probability that a random individual in the relevant population would share the same phenotype. In Europeans, the most common Rh phenotype is DCcee (R1r), present in about 33% of the population; a match to this phenotype carries less discriminating weight than a match to a rarer phenotype such as DCCee or DccEE.

Conventional Rh serology requires intact red cell membranes: the D antigen is a membrane-spanning protein that loses structural integrity as cells lyse and degrade. Fresh bloodstains on non-porous surfaces can sometimes be typed within a few days of deposition using the absorption-elution technique, in which anti-D reagent is absorbed onto the stain at low temperature and then eluted by heating; the eluted antibody is tested for its specificity against D-positive and D-negative indicator cells. The method works on substrates such as fabric and leather but becomes unreliable after weeks of environmental exposure, particularly in warm or humid conditions.

PCR-based RHD genotyping from DNA extracted from dried bloodstains has substantially replaced serological Rh typing in modern forensic laboratories. DNA is more stable than protein antigens in aged or environmentally stressed samples. The standard molecular approach targets unique RHD-specific exon sequences (exons 4, 5, 7, and 10 are commonly used) that are absent in individuals who have undergone RHD gene deletion. A positive amplification result indicates the RHD gene is present and the individual is likely Rh-positive; failure to amplify, combined with successful amplification of a control gene, indicates RHD deletion and Rh-negative status.

The statistical weight of an Rh phenotype match between a crime scene stain and a suspect depends on phenotype frequency in the relevant population. A result showing the suspect and the stain are both D-positive adds little discriminating information in a European population where 85% of people are D-positive. Full Rh phenotyping, including C, c, E, and e, produces a rarer phenotype combination with greater exclusion value, but even the full five-antigen phenotype is far less discriminating than a standard STR DNA profile. Rh typing results from forensic evidence are best interpreted as supportive information within a wider evidence set rather than as stand-alone identifiers.

Before DNA profiling, blood group systems including Rh were the primary tools for paternity exclusion. The logic is Mendelian: a child must inherit one Rh haplotype from each parent, so an antigen present in the child but absent in both the mother and the alleged father constitutes an exclusion. The D antigen alone provides only a binary exclusion: if the child is D-positive and the alleged father is homozygous Rh-negative (cde/cde), paternity is excluded because the father has no D haplotype to transmit.

The C, c, E, and e antigens add resolution. A child who expresses the E antigen when neither the mother nor the alleged father carries a haplotype with E (cDE or CDE) is excluded, regardless of D status. Combining all five Rh antigens with ABO, MNS, Kell, Duffy, and Kidd systems in classical serology could achieve a combined non-paternity exclusion probability of around 70% to 80%, meaning that a falsely accused man had roughly a 70% to 80% chance of being excluded by blood group typing. While useful, this also meant 20% to 30% of falsely accused men could not be excluded.

In current forensic practice across most jurisdictions, STR-based DNA profiling has replaced blood group paternity testing. A standard panel of 15 to 20 STR loci produces a combined paternity index that typically exceeds 99.999% probability of paternity when the tested man is not excluded, and STR profiling can exclude a non-father with near certainty. The United Kingdom's Family Law Reform Act 1969 and the US Uniform Parentage Act, and their equivalents in other countries including the Indian DNA Technology (Use and Application) Regulation Bill framework, all recognise DNA-based parentage testing as the standard. Rh and other blood group evidence may still appear in older case records or in jurisdictions where DNA is not yet routinely available.

One application where Rh serology retains practical value is the determination of biological sex from blood, because the Rh antigens are expressed equally regardless of sex and provide a population frequency reference independent of sex-linked markers. Rh typing also contributes to population genetics studies and ancestry estimation in anthropological forensic casework, because Rh haplotype frequencies differ meaningfully between continental populations.

Rh-negative frequency varies substantially across human populations. Approximately 15% to 17% of people of European descent are Rh-negative (cde/cde genotype), making Europe the population with the highest Rh-negative frequency globally. Among people of sub-Saharan African ancestry, Rh-negative frequency is approximately 5% to 8%. In East Asian, South Asian, and Indigenous American populations, Rh-negative frequency is typically below 1%, with some populations approaching 0%. The D antigen is therefore an almost universal marker in many non-European populations, reducing its forensic discriminating power in those demographic contexts.

The C and E antigen frequencies also vary. The cDE (R2) haplotype, which carries the E antigen, is more common in people of Asian descent than in Europeans. The Cde (r') haplotype, which carries C without D, is uncommon in all populations. These differences mean that the statistical weight assigned to an Rh phenotype match must use population-specific frequency data, not global averages. Using an incorrect reference population inflates or deflates the apparent rarity of the phenotype and produces a misleading likelihood ratio.

Rh antigen frequencies were historically catalogued through population surveys using serological typing of blood donors, and these reference databases underlie the frequency tables used in forensic calculations. More recent population genomics projects, including the 1000 Genomes Project and gnomAD, have confirmed and extended Rh haplotype frequency data through RHD and RHCE genotyping at scale. Forensic analysts should verify that their reference frequency database is appropriate for the demographic context of the case, and should disclose which population dataset was used when presenting Rh typing evidence in court.

Courts in multiple jurisdictions have admitted Rh blood group evidence as part of serological analysis for decades, though its role has diminished as DNA profiling became standard. In the United States, blood group evidence was admitted under the general acceptance standard articulated in Frye v. United States (1923), later superseded by the Daubert standard (Daubert v. Merrell Dow Pharmaceuticals, 1993) requiring scientific validity, testability, peer review, and known error rates. Rh serological typing satisfies these criteria. In the United Kingdom, forensic evidence standards under the Criminal Procedure Rules 2020 and the Crown Prosecution Service guidance on expert evidence require disclosure of the method's limitations, including population frequency assumptions.

In India, forensic serological evidence including blood group typing is admissible under the Bharatiya Sakshya Adhiniyam 2023 (which replaced the Indian Evidence Act 1872), which recognises expert opinion evidence and documentary evidence of scientific testing results. The European Union's approach to forensic evidence standards, coordinated through the European Network of Forensic Science Institutes (ENFSI), promotes accreditation of forensic laboratories to ISO 17025 and requires validation of all typing methods used in casework. Rh typing methods in accredited laboratories are subject to documented validation, proficiency testing, and quality assurance requirements.

Expert witnesses presenting Rh typing results must communicate both the positive finding and its statistical weight honestly. Stating that a suspect and a bloodstain are both Rh-positive without also stating that 85% of the relevant population shares that trait is misleading. The appropriate format is to present the result alongside the population frequency of the phenotype and, where possible, a likelihood ratio comparing the probability of the result if the suspect is the source versus if a random person from the population is the source. The minor blood group systems topic at Minor Blood Group Systems describes how additional systems can be combined with Rh typing to improve discriminating power.